Zhongshan Daxue xuebao. Yixue kexue ban, 2002 【目的】研究心肌腺苷预处理和缺血预处理对离体大鼠心脏缺血/再灌注后心肌功能的影响。【方法】以离体大 白鼠工作心脏模型, 比较经腺苷预处理和缺血预处理, 心肌缺血再灌前后左室压、左室舒张末期压、左心室内压上升及下降最 大速率、主动脉压、冠脉流量、主动脉流量和测定冠脉流出液乳酸脱氢酶(LDH), 心肌ATP 含量、超氧化物岐化酶(SOD)活性、 脂质过氧化物含量及自灌注停搏液至完全停搏的时间。【结果】腺苷预处理和缺血预处理产生相似的心肌保护作用, 明显促 进心肌缺血再灌后心肌功能的恢复 ...
周必强, 叶世铎
doaj
[Isovitexin alleviates myocardial oxidative stress injury in diabetic mice by enhancing myocardial SIRT3 expression and reducing oxidative stress]. [PDF]
Nan Fang Yi Ke Da Xue Xue BaoPeng Y +6 more
europepmc +1 more source
[Overwork damages myocardial energy metabolism homeostasis in mice]. [PDF]
Nan Fang Yi Ke Da Xue Xue BaoCui J +6 more
europepmc +1 more source
Zhongshan Daxue xuebao. Yixue kexue ban, 2010 目的】 研究AMP激活的蛋白激酶 (AMPK)及血红素氧合酶HO-1激活对心肌肥大的影响,以及HO-1在AMPK抑制心肌肥大中的作用?【方法】 以培养的新生大鼠心肌细胞为研究对象,采用蛋白免疫印迹杂交方法检测5-氨基-4甲酰胺咪唑核糖核苷酸(AICAR)对AMPK的磷酸化程度及对HO-1的影响,并测定心肌细胞 [3H]-亮氨酸掺入率及心肌细胞表面积,观察AMPK及HO-1心肌细胞肥大的影响?【结果】 AICAR对AMPK及HO-1均有激活作用,AICAR能阻断AngⅡ引起的心肌肥大效应;阻断HO ...
doaj
[Application of molecularly imprinted polymers-based sensors for determination of acute coronary syndrome biomarkers]. [PDF]
Se PuZhang Y +6 more
europepmc +1 more source
[Shihu Mixture alleviates diabetic cardiomyopathy in rats by Sirt3-mediated upregulation of myocardial mitochondrial mitophagy pathway]. [PDF]
Nan Fang Yi Ke Da Xue Xue BaoLin X, He Y, Shi H, Liu J, Hu H.
europepmc +1 more source
[Liver-bone axis: novel mechanisms and strategies for MAFLD regulation]. [PDF]
Zhonghua Gan Zang Bing Za ZhiWang YW, Yan XZ, You H, Yang AT.
europepmc +1 more source
[Expression of the melanoma 2-mediated pyroptosis pathway in peripheral blood mononuclear cells of patients with idiopathic inflammatory myopathies]. [PDF]
Beijing Da Xue Xue Bao Yi Xue BanChu J +6 more
europepmc +1 more source
[Exosome-derived miR-1275 mediates IL-38 upregulation in lymphocytes to suppress lipopolysaccharide-induced apoptosis of myocardial cells <i>in vitro</i>]. [PDF]
Nan Fang Yi Ke Da Xue Xue BaoBo H, Cao X, Xing P, Wang Z.
europepmc +1 more source
[β‑blockers after percutaneous coronary intervention does not reduce risks of all-cause mortality or major adverse cardiovascular events in patients with stable coronary artery disease]. [PDF]
Nan Fang Yi Ke Da Xue Xue BaoGao X +7 more
europepmc +1 more source